Assessment of Biologic Treatments for Severe Chronic Rhinosinusitis with Nasal Polyps in a Real-Life Setting

What this Trial Is About

Chronic Rhinosinusitis with Nasal Polyps CRSwNP affects 2-4% of people in western countries and significantly reduces quality of life. This condition involves a specific immune response leading to inflammation and nasal polyps. Researchers are evaluating biologic treatments that target these immune pathways to better manage CRSwNP, aiming to improve patient quality of life and tailor treatments using biomarkers in this prospective study. The study monitors patients with severe CRSwNP who receive biologic drugs such as dupilumab, mepolizumab, or benralizumab given by subcutaneous injection every two weeks or every month, depending on marketing approvals. Some patients already treated since August 2021 will have their past clinical and biological data collected retrospectively. The study plans a follow-up period of 5 years to assess treatment impact and tolerance. Participants will provide patient-reported outcomes regularly, with evaluations at treatment start, 3 months, 6 months, and every 6 months up to 5 years. Researchers will track quality of life changes, symptom progression, time to any surgical procedures, and blood markers including eosinophil count and total IgE levels. This detailed monitoring aims to understand how biologic therapies affect CRSwNP over the long term and ensure patient safety and compliance.

BIOlogics in Severe Nasal POlyposis SurvEy.: a French Registry